Jubilant Pharmova profit and loss

Latest FY26

Revenue: ₹8,280cr+14.4% on FY25
EBITDA: ₹1,260cr+7.3% on FY25
Net profit: ₹398cr−52.5% on FY25
EPS: ₹25.15−52.5% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	8,608	8,280	7,235	6,703	6,282	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	73.9	66.0	56.8	68.7	38.3
	8,682	8,346	7,291	6,772	6,320
	2,438	2,320	1,985	1,821	1,666
	327	313	297	241	252
	9.7	10.9	34.6	78.2	−40.7
	2,863	2,701	2,268	2,216	2,166
	217	212	240	272	188
	470	440	369	382	554
	1,752	1,675	1,476	1,445	1,462
	8,077	7,672	6,670	6,456	6,248
	1,218	1,260	1,174	901	776
	749	819	805	519	222
Profit
	606	674	622	315	72.4
	−59.2	−59.2	360	−169	−56.8
	546	614	981	146	15.5
	153	161	213	203	181
	41.9	55.9	−68.9	−105	−88.4
	195	217	144	97.8	92.7
	−0.2	−0.3	−0.5	24.1	12.3
	351	398	836	72.7	−64.9
	352	398	837	48.6	−77.1
	486	546	85.0	54.4	220
	837	943	921	127	156
	352	399	839	77.1	−61.0
	−0.7	−1.0	−3.1	−4.4	−3.9
Per share
	₹22.23	₹25.15	₹52.99	₹4.87	−₹3.83
	₹22.17	₹25.08	₹52.85	₹4.86	−₹3.83
Other comprehensive income — detail
	486	546	85.0	—	—
	6.9	6.4	−0.3	5.8	−14.5
	0.0	−0.1	−0.8	1.1	−0.9
	—	—	—	1.1	−0.9
	—	—	84.5	49.7	234
	−275	−539	0.0	—	—
	838	945	925	132	160
	−1.2	−1.6	−3.4	−4.6	−4.2
Per share — as-filed variants
	₹22.23	₹25.15	₹52.99	₹4.87	−₹3.83
	₹22.17	₹25.08	₹52.85	₹4.86	−₹3.83
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	5,834	5,635	4,918	4,562	4,404
	67.8%	68.1%	68.0%	68.1%	70.1%
Adjusted (ex-exceptional items) — derived
	606	674	622	315	72.4
	−59.2	−59.2	360	−169	−56.8
	390	436	530	140	−42.2
	₹24.64	₹27.58	₹33.56	₹9.40	−₹2.49

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

JUBLPHARMA₹943.90

Jubilant Pharmova Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersGLAND PPLPHARMA KIMS INDGN ONESOURCE GRANULES PFIZER POLYMEDMcap ₹14,914 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	6,281.7	6,702.9	7,234.5	8,279.6	8,608.3
Other Income	38.3	68.7	56.8	66.0	73.9
Total Income	6,320.1	6,771.6	7,291.3	8,345.6	8,682.2
Expenses
+ Cost of Materials Consumed	1,666.4	1,821.3	1,985.3	2,320.3	2,438.1
+ Purchases of Stock-in-Trade	252.2	241.2	297.1	313.1	327.0
+ Changes in Inventories	-40.7	78.2	34.6	10.9	9.7
+ Employee Benefit Expense	2,166.0	2,216.0	2,267.9	2,700.6	2,863.0
+ Finance Costs	188.2	272.3	240.3	211.8	217.0
+ Depreciation & Amortisation	554.0	381.9	368.6	440.4	469.6
+ Other Expenses	1,461.5	1,445.4	1,475.9	1,674.9	1,752.3
Total Expenses	6,247.7	6,456.3	6,669.7	7,672.0	8,076.7
EBITDA	776.3	900.8	1,173.7	1,259.8	1,218.2
EBIT	222.2	518.9	805.1	819.4	748.6
Profit
PBT before Exceptional Items	72.4	315.3	621.6	673.6	605.5
+ Exceptional Items	-56.8	-168.9	359.5	-59.2	-59.2
Pretax Income	15.5	146.4	981.1	614.4	546.3
+ Current Tax	181.1	202.6	213.2	160.7	152.8
+ Deferred Tax	-88.4	-104.8	-68.9	55.9	41.9
Tax Expense	92.7	97.8	144.3	216.6	194.7
+ Share of Associates & JVs	12.3	24.1	-0.5	-0.3	-0.2
Net Income	-64.9	72.7	836.3	397.5	351.4
+ Net Income — Continuing Ops	-77.1	48.6	836.8	397.8	351.6
+ Other Comprehensive Income	220.4	54.4	85.0	545.8	485.6
Total Comprehensive Income	155.6	127.1	921.3	943.3	837.0
Net Income to Common	-61.0	77.1	839.4	398.5	352.1
Minority Interest	-3.9	-4.4	-3.1	-1.0	-0.7
Per Share
Basic EPS	-3.83	4.87	52.99	25.15	22.23
Diluted EPS	-3.83	4.86	52.85	25.08	22.17
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	85.0	545.8	485.6
+ Items NOT to be Reclassified to P&L	-14.5	5.8	-0.3	6.4	6.9
+ Tax on Items NOT to be Reclassified	-0.9	1.1	-0.8	-0.1	0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.9	1.1	—	—	—
+ Items to be Reclassified to P&L	234.1	49.7	84.5	—	—
+ Tax on Items to be Reclassified	—	—	0.0	-539.3	-274.6
Comprehensive Income — Owners of Parent	159.8	131.7	924.7	944.9	838.2
Comprehensive Income — Non-controlling Interests	-4.2	-4.6	-3.4	-1.6	-1.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	-3.83	4.87	52.99	25.15	22.23
Diluted EPS — Continuing Operations	-3.83	4.86	52.85	25.08	22.17
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	4,403.8	4,562.2	4,917.5	5,635.3	5,833.5
Gross Margin %	70.10	68.06	67.97	68.06	67.77
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	72.4	315.3	621.6	673.6	605.5
− Exceptional Items (reconciliation)	-56.8	-168.9	359.5	-59.2	-59.2
Net Income Adj (tax-effected)	-42.2	140.3	529.7	435.8	389.5
EPS Adj	-2.49	9.40	33.56	27.58	24.64
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	15.9	15.8	15.8	15.8	15.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.